Voegeli, M., Rondeau, S., Berardi Vilei, S., Lerch, E., Wannesson, L., Pabst, T., Rentschler, J., Bargetzi, M., Jost, L., Ketterer, N., Bischof Delaloye, A., & Ghielmini, M. (n.d.). y90‐Ibritumomab tiuxetan (Y90‐IT) and high‐dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05). Hematological oncology, 35(4), 576–583. http://access.bl.uk/ark:/81055/vdc_100055218731.0x000046